Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab Neoadjuvant for NSCLC (NATAL)
NCT05295212Phase 2Recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Hunan Cancer Hospital. Started Feb 2023; status: recruiting.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05295212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05295212.